Highlights Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Real-time Estimate Cboe BZX Other stock markets 03:04:11 2024-04-29 pm EDT			5-day change	1st Jan Change
7.04 ^USD	+2.47%		+4.12%	-3.42%

Mar. 26	Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	MT
Mar. 26	Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	Mar. 26	MT
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	Mar. 26	CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000	Feb. 29	MT
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	Jan. 29	CI
Ligand Pharma's at-home skin treatment gets FDA approval	Jan. 05	RE
Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315	Jan. 05	CI
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH?? for the Treatment of Common Warts	Jan. 04	CI
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH?	Jan. 03	CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Posts Q3 Revenue $2.9M, vs. Street Est of $470,000	Nov. 09	MT
Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises	23-08-24	CI
Verrica Pharmaceuticals Inc. Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma At the American Academy of Dermatology 2023 Innovation Academy Meeting	23-08-10	CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's 2023 Innovation Academy Meeting	23-08-03	CI
Verrica Pharmaceuticals Gets US FDA Approval for Ycanth to Treat Molluscum Contagiosum; Shares Drop Premarket	23-07-24	MT
Verrica Pharmaceuticals Gets US FDA Approval for Ycanth to Treat Molluscum Contagiosum	23-07-21	MT
US FDA approves Verrica's skin disease treatment	23-07-21	RE
Verrica Pharmaceuticals Inc. Announces FDA Approval of YCANTH? (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum	23-07-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Highlights

Filters